Central Serous Choroidopathy Clinical Trial
Official title:
A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy
The purpose of this study is to observe whether micropulse laser (MPL) is noninferiority to traditional laser therapy in central serous chorioretinopathy.
Central serous chorioretinopathy (CSC) is characterized by serous detachment of neurosensory
retina which can cause lose in visual acuity. Some studies have shown that traditional laser
treatment (TLT) is effective on CSC, although accompanied with side-effects, such as scar.
Recent retrospective studies suggest micropulse laser (MPL) therapy may also be effective
without obvious complications in this disease. But to date, there is no study on
effectiveness of CSC between TLT and MPL.
The study is the first prospective randomized controlled trial about 577nm micropulse laser
versus traditional laser treatment in central serous chorioretinopathy. It is a
noninferiority study. The investigators hypothesize that application of 577nm micropulse
laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence
tomography and best corrected visual acuity.This will be a pilot study to establish sound
methods and provide some insights to the safety and efficacy of CSC treatment. The primary
outcome measures is the change of BCVA in 12 week.
;